Eco Animal Health Group (EAH) Stock Rating Reaffirmed by Peel Hunt

Share on StockTwits

Peel Hunt reiterated their buy rating on shares of Eco Animal Health Group (LON:EAH) in a research note published on Tuesday morning.

Separately, Liberum Capital restated a buy rating and set a GBX 725 ($9.35) price target on shares of Eco Animal Health Group in a report on Monday, July 2nd.

Shares of LON EAH opened at GBX 500 ($6.45) on Tuesday. Eco Animal Health Group has a 1-year low of GBX 485 ($6.26) and a 1-year high of GBX 680 ($8.77).

The business also recently declared a dividend, which will be paid on Wednesday, October 17th. Shareholders of record on Thursday, September 27th will be issued a dividend of GBX 6 ($0.08) per share. This is an increase from Eco Animal Health Group’s previous dividend of $3.20. The ex-dividend date is Thursday, September 27th. This represents a yield of 1.1%.

In other Eco Animal Health Group news, insider Anthony Paul Rawlinson sold 60,000 shares of the company’s stock in a transaction dated Tuesday, August 28th. The stock was sold at an average price of GBX 500 ($6.45), for a total transaction of £300,000 ($386,996.90).

About Eco Animal Health Group

ECO Animal Health Group plc develops and markets pharmaceutical products for animals worldwide. The company offers Aivlosin, a macrolide antibiotic for the treatment of respiratory and enteric diseases in pigs and poultry. It also provides generic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic, which are endectocides and other antiparasitics for the treatment and prevention of parasites in cattle, sheep, pigs, horses, and dogs; and Chlortetracycline and Oxytetracycline for treatment of bacterial infections in pigs, poultry, and cattle.

Recommended Story: Short Selling Stocks and Day Traders

Receive News & Ratings for Eco Animal Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eco Animal Health Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply